Morgan Stanley raised the firm’s price target on Akero Therapeutics (AKRO) to $96 from $46 and keeps an Overweight rating on the shares after 96-week data from its Phase 2b SYMMETRY study of efruxifermin in tough-to-treat F4 cirrhotic patients with metabolic dysfunction-associated steatohepatitis were better than expected, demonstrating statistical significant improvements on fibrosis. The firm believes the results are “groundbreaking,” confirming the antifibrotic effects of efruxifermin in more challenging F4 patients, the analyst tells investors.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics price target raised to $73 from $56 at Canaccord
- Akero Shares Skyrocket as MASH Drug Delivers Game-Changing Results
- Akero Therapeutics price target raised to $80 from $65 at Citi
- Akero Therapeutics announces $300M common stock offering
- Madrigal dip on Akero data a buying opportunity, says Evercore ISI